Historical progress in the initial management of ovarian cancer: Intraperitoneal chemotherapy
- 50 Downloads
Despite measured improvement in survival with the introduction of the platinates and taxanes in treatment of advanced ovarian cancer, little additional progress has been made with conventional cytotoxic agents. Recently, the Gynecologic Oncology Group (GOG) published data from a study evaluating the merits of intraperitoneal chemotherapy in women with advanced, optimally cytoreduced ovarian cancer. They documented a significant advantage in progression-free and overall survival for the experimental regimen, a combination of intravenous paclitaxel and intraperitoneal cisplatin and paclitaxel, compared with standard intravenous cisplatin and paclitaxel chemotherapy. The intraperitoneal regimen was substantially more toxic and was associated with reduced short-term quality of life. The GOG trial joins six other published phase III trials since 1994 comparing intravenous with intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancer. A recent meta-analysis suggests a 21% reduction in the hazard for progression (four studies) and death (seven studies). Reluctance to adopt a new standard of care is rooted in toxicity concerns. Further evaluation is warranted to clarify unanswered questions regarding administration schedule, agents, techniques, number of courses, and patient eligibility for intraperitoneal chemotherapy.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 16.Zylberberg B, Ravina JH, Salat-Baroux J, et al.: [Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results]. J Gynecol Obstet Biol Reprod (Paris) 1986, 15:671–676.Google Scholar
- 20.Gadducci A, Carnino F, Chiara S, et al.: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest Gynecol Oncol 2000, 76:157–162.PubMedCrossRefGoogle Scholar
- 21.Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001–1007.PubMedGoogle Scholar
- 23.Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34–43. Phase III trial evaluating merits of intraperitoneal cisplatin and paclitaxel in initial ovarian cancer management. Also first trial to report the impact of therapy on health-related quality of life.PubMedCrossRefGoogle Scholar
- 24.Jaaback K, Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006, CD005340. Well written and concise meta-analysis of intraperitoneal chemotherapy trials.Google Scholar
- 25.Alert NCIC: Intraperitoneal chemotherapy for ovarian cancer. Bethesda, MD; 2006.Google Scholar
- 30.Walker JL, Armstrong DK, Huang HQ, et al.: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2006, 100:27–32. Extensive report of catheter complications accompanying GOG Protocol #172.PubMedCrossRefGoogle Scholar
- 36.Aravantinos G, Fountzilas G, Kosmidis P, et al.: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2005, 16:1116–1122.PubMedCrossRefGoogle Scholar